MBX Bio - Total Utang marang Modal MBX

MBX Bio - logo grafis emiten MBX

This chart illustrates that the market valuation of the total debt-to-equity ratio for MBX Biosciences Inc (MBX) is 0.01. The company develops innovative treatments for hormonal imbalances in US centers, leveraging exclusive engineering developments. Since the firm is in the testing phase and has no sales, its operations consist of converting investments into scientific research. This approach makes the asset a resilient defensive asset, independent of global economic fluctuations.

MBX Biosciences (MBX): Rasio Kabeh Utang marang Dana Pribadi saka 14.09.2024 nganti 31.10.2026

Rincian analitis lan laporan data perusahaan MBX Corp (MBX)

- rega saham lan konsensus proyeksi valuasi:
Rega saham MBX Biosciences|MBX - Konsensus nilai wajar
- rincian nilai pasar emiten:
Kapitalisasi pasar MBX Biosciences|MBX - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham MBX Biosciences|MBX - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku mbxbio.com|MBX - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal MBX Biosciences Inc|MBX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas MBX Biosciences Inc|MBX - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku MBX Biosciences|MBX - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan MBX Biosciences|Indikator likuiditas cepet mbxbio.com
- data bathi resik lan rasio valuasi:
MBX - Bathi sawise mbayar pajeg
Pambiji fundamental perusahaan:MBX, MBX Biosciences
Produk dadi mbxbio.com

The logistics stability of endocrine drugs from MBX Biosciences Inc (MBX) requires a precise balance between debt and equity financing. This metric is calculated as the ratio of total liabilities to net equity, measuring the degree of financial leverage. By analyzing the debt-to-equity financial dependency trend on GURU.Markets, an investor can see the impact of the stock's market value on business sustainability. Low leverage confirms the reliability of supply chains, while an optimal debt level maximizes the issuer's overall return on assets.

Analisis perusahaan pesaing

ASND (Ascendis Pharma) - Total Utang marang Modal|MDGL: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal CORT|Total Utang marang Modal Rhythm Corp (RYTM)|Utang marang Ekuitas Akero Therapeutics AKRO|Rasio Kabeh Utang marang Dana Pribadi MTSR|MLTX - Utang marang Ekuitas|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio Total Utang marang Ekuitas|NAMS: Total Utang marang Modal|Soleno Therapeutics Corp (SLNO) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas FOLD|ETNB: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Agios Pharmaceuticals, Inc. (AGIO)|Rasio Total Utang marang Ekuitas Structure Therapeutics Inc GPCR|Total Utang marang Modal MDXG (MiMedx Group)|Rezolute Bio (RZLT) - Utang marang Modal|LXRX: Rasio Total Utang marang Ekuitas|altimmune.com - Utang Agregat marang Modal|AARD: Total Utang marang Modal|Sagimet Biosciences, Inc. (SGMT) - Total Utang marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Utang marang Ekuitas BMEA|Utang marang Ekuitas Quince Therapeutics (QNCX)|GUTS - Utang marang Modal|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp - Utang marang Ekuitas|Pluri Inc - Total Utang marang Modal|Koefisien Total Utang marang Modal Synlogic, Inc. SYBX|Lipocine Inc. (LPCN) - Utang marang Ekuitas|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Rasio Total Utang marang Ekuitas Galecto Inc (GLTO)|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Total Utang marang Modal ONVO (Organovo Holdings, Inc.)|radiuspharm.com - Utang marang Ekuitas